NRG ONCOLOGY published Protocol Activation NRG-GY038, a randomized Phase II trial comparing Sacituzumab Govitecan-Hziy (SG) and Bevacizumab with standard of care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in patients with platinum-sensitive ovarian cancer progressing on prior maintenance PARP inhibitor.
Public source
Publisher name
Public post
Protocol Activation NRG-GY038: A Randomized Phase II Trial of Sacituzumab Govitecan-Hziy (SG) and Bevacizumab versus Standard of Care Carboplatin, Pegylated Liposomal Do…
Company
NRG ONCOLOGY
Advancing Research. Improving Lives.
- Industry
- Non-profit Organizations
- Location
- PHILADELPHIA, US
- Company size
- 51–200 employees
About NRG ONCOLOGY
NRG Oncology is a non-profit research organization formed to conduct oncologic clinical research and to broadly disseminate study results for informing clinical decision making and healthcare policy.
See moreLatest activity
Latest activity from NRG ONCOLOGY
8 signals
Legal & Regulatory
NRG ONCOLOGY closed all NRG Oncology Operations offices, SDMCs, and Biospecimen Banks today in observance of Labor Day
Presence & Recognition
NRG ONCOLOGY is hosting an interview with Dr. Ying Liu regarding the NRG-GY036 for ovarian, fallopian tube, and peritoneal cancers for the Ovarian Cancer Awareness Month.
Presence & Recognition
NRG ONCOLOGY featured ovarian cancer advocate Debbie in a participation powers research feature for WearTealDay
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
UCL Innovative Clinical Trials Unit
UCL Innovative Clinical Trials Unit published results from the ICON8B trial showing that women who received weekly chemotherapy alongside bevacizumab lived longer than those who received chemotherapy every three weeks for advanced ovarian cancer patients.
Research & Knowledge
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology announced that the PAGODA Trial is enrolling patients with gastrointestinal cancers led by Gabriel Brooks, MD, MPH.
Research & Knowledge
Starling Oncology
Starling Oncology published a blog post detailing ovarian cancer symptoms, risk factors, risk-reduction strategies, and available support.
Research & Knowledge
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals published the study titled Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib in JCO Precision Oncology.
Research & Knowledge
Lung Cancer Foundation of America